<DOC>
	<DOC>NCT00624390</DOC>
	<brief_summary>The purpose of this research study is to obtain preliminary data of the safety and effectiveness of Sepraspray in a limited number of patients who are under going a laparoscopic myomectomy. Sepraspray will be applied to the organs in the pelvic cavity following laparoscopic myomectomy. We will compare treatment with Sepraspray as a adhesion prevention barrier after laparoscopic myomectomy versus no adhesion barrier.</brief_summary>
	<brief_title>Seprasprayâ„¢ Laparoscopic Myomectomy Study</brief_title>
	<detailed_description />
	<criteria>The patient must be a premenopausal women with myomas associated with clinical symptoms deemed suitable for laparoscopic myomectomy and SLL. Pregnant/lactating women. The patient has a history of hypersensitivity to exogenous carboxymethylcellulose products and/or hyaluronic acid. The patient's procedure resulted in entry of the endometrial cavity, or entry of the bowel including appendectomy.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>